Loading stock data…
$85.03+0.80 (+0.95%)
Henry Schein, Inc.
Henry Schein, Inc. in the Healthcare sector is trading at $85.03 with a market capitalization of $10.0B. Wall Street consensus targets $97.27 (15 analysts), implying a +14.4% move over the next 12 months. The stock is currently 8% below its 52-week high of $92.18, remaining 5.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.46B↑ | $3.37B↓ | $3.44B↑ | $3.34B↑ | $3.24B |
| Gross Profit | $1.10B↑ | $1.07B↑ | $1.06B↑ | $1.03B↑ | $1.02B |
| Operating Income | $200.00M↑ | $194.00M↑ | $186.00M↓ | $198.00M↑ | $174.00M |
| Net Income | $94.00M↓ | $107.00M↑ | $101.00M | $101.00M↑ | $86.00M |
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The...
Academic risk and quality models computed from HSIC's own filings and price history, not from analyst opinion.
Mixed: 4 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z in the 1.81 to 2.99 grey zone, the band where the model gives no clear bankruptcy verdict.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 23.0% reading.
Fama-French 5-factor market beta. The five factors explain 24% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-13.